Welcome: HKGP Anabolics - HKGOTOPHARM - High Quality Steroid Powder Supplier

Home > Products > Tirzepatide Peptide

  • Tirzepatide Peptide
  • Tirzepatide Peptide
Tirzepatide PeptideTirzepatide Peptide

Tirzepatide Peptide

  • Category: Products
  • Views:5962
  • Tirzepatide Peptide Powder
  • 10mg sample available
  • 1g minimum order
  • LAB TEST
  • Product description:Tirzepatide Peptide, Tirzepatide buy china. Tirzepatide Peptide for sale china
  • Order online

Tirzepatide Peptide Powder from China. Tirzepatide buy china. Tirzepatide Peptide for sale china


Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes.  Controlling high blood sugar helps prevent kidney damage, blindness,  nerve problems, loss of limbs, and sexual function problems.
Pharmacology Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity and is currently under regulatory review as a treatment for adults with type 2 diabetes. It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH) and heart failure with preserved ejection fraction (HFpEF). Studies of tirzepatide in obstructive sleep apnea (OSA) and in morbidity/mortality in obesity are planned as well.
Side effects The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies that have been approved for the treatment of obesity. This said, reported side effects were considerable, especially as dosage levels increased. The most common adverse events were nausea (~30%), diarrhea (~20%), constipation (~15%) and vomiting (~10%).
If tirzepatide gets approved as a both a blood glucose control and anti-obesity agent, it could become a blockbuster drug. However, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments.
Mode of action Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behaviour has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies have shown that this is due to tirzepatide mimicking the actions of natural GIP at the GIP receptor. However, at the GLP-1 receptor, tirzepatide shows bias towards cAMP (a messenger associated with regulation of glycogen, sugar and lipid metabolism) generation, rather than β-arrestin recruitment. This combination of preference towards GIP receptor and distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion. Tirzepatide has also been shown to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage.

PREVIOUS:Semaglutide Peptide No next

CONTACT US

Name: Mr. James

Mobile:Telegram 0086 171,8678,5083

Tel:Whatsapp: 0086 171,8678,5083

Email: jamesh01@pm.me

Add:No.38, Guangda rd, Longgang Avenue, SZ. 518116, Guangdong, China


Top footer
Contact us Close

Company: HKGP Anabolics - HKGOTOPHARM - High Quality Steroid Powder Supplier

Contact: Mr. James

Tel: Whatsapp: 0086 171,8678,5083

Phone: Telegram 0086 171,8678,5083

E-mail: jamesh01@pm.me

Address: No.38, Guangda rd, Longgang Avenue, SZ. 518116, Guangdong, China